BioXcel Therapeutics Stock Tumbles: Company Releases Mixed Results From Lower Dose Igalmi Study In Bipolar/Schizophrenia Associated Agitation
Portfolio Pulse from Vandana Singh
BioXcel Therapeutics announced mixed results from Part 1 of Phase 3 SERENITY III trial for BXCL501, a lower dose of Igalmi, in bipolar and schizophrenia-associated agitation. The results will enable the initiation of Part 2 for at-home use. BTAI shares are down 27.5%.
May 25, 2023 | 5:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BioXcel Therapeutics' stock tumbles after mixed results from lower dose Igalmi study in bipolar/schizophrenia-associated agitation.
The mixed results from the Phase 3 SERENITY III trial for BXCL501, a lower dose of Igalmi, have led to uncertainty about the drug's efficacy and future prospects. This has caused a negative impact on BioXcel Therapeutics' stock price, with shares down 27.5%.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100